
Bionano Genomics (BNGO) Stock Forecast & Price Target
Bionano Genomics (BNGO) Analyst Ratings
Bulls say
Bionano Genomics demonstrated significant growth in its sales, with the sale of 7,233 nanochannel array flowcells in 2Q25, marking a 17% increase from the 6,165 flowcells sold in 2Q24. Adjusted revenue from consumables, software, and remaining services saw an 11% year-over-year increase in 2Q25, with a notable 16% rise in consumables and software revenues. Furthermore, the company anticipates an increase in new OGM installations for FY2025, projecting 20-25 installations compared to 15-20 in the previous year, reflecting a positive trajectory in expansion and product adoption.
Bears say
Bionano Genomics is facing a negative outlook primarily due to several financial and operational risks, including lower-than-projected market uptake and utilization of its products and systems. Despite a projected sales per share of $6.50 and net cash of $3.28 per share, the conservative EV/Revenue multiple of 1.2x suggests underlying challenges that may impede revenue growth, leading to a price objective of approximately $11. The company also faces significant financial risks, such as the inability to secure additional capital for operations and potential dilution of shares.
This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.
Bionano Genomics (BNGO) Analyst Forecast & Price Prediction
Start investing in Bionano Genomics (BNGO)
Order type
Buy in
Order amount
Est. shares
0 shares